We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | NASDAQ:INO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.42 | 3.62% | 12.01 | 11.37 | 12.17 | 12.105 | 11.5071 | 11.87 | 266,668 | 22:41:02 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2020
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-14888 | 33-0969592 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
660 W. Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
(Address of principal executive offices, including zip code)
(267) 440-4200
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
Common Stock, $0.001 par value | INO | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On May 14, 2020, Inovio Pharmaceuticals, Inc. (the Company) held its 2020 Annual Meeting of Stockholders (the Annual Meeting). At the Companys Annual Meeting, the stockholders considered three proposals, each of which is described in more detail in the Companys definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2020. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal 1: The election of the following nominees as directors of the Company to serve until the Companys 2021 Annual Meeting of Stockholders and until their successors are elected. The votes were cast as follows:
Name of Director Nominee |
Votes For |
Votes
Withheld |
Broker
Non-Votes |
|||||||||
Simon X. Benito |
30,575,942 | 1,150,924 | 70,245,437 | |||||||||
J. Joseph Kim, Ph.D. |
30,744,561 | 982,305 | 70,245,437 | |||||||||
Ann C. Miller, Ph.D. |
30,763,223 | 963,643 | 70,245,437 | |||||||||
Jay P. Shepard |
30,903,310 | 823,556 | 70,245,437 | |||||||||
David B. Weiner, Ph.D. |
30,939,582 | 787,284 | 70,245,437 | |||||||||
Wendy L. Yarno |
30,680,330 | 1,046,536 | 70,245,437 | |||||||||
Lota S. Zoth |
30,693,799 | 1,033,067 | 70,245,437 |
Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2020. The votes were cast as follows:
For |
Against |
Abstain |
Broker
|
|||
99,024,317 |
1,720,013 | 1,227,973 | 0 |
Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the Companys named executive officers described in the Companys definitive proxy statement with respect to the Annual Meeting. The votes were cast as follows:
For |
Against |
Abstain |
Broker
|
|||
27,543,808 |
2,932,479 | 1,250,579 | 70,245,437 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INOVIO PHARMACEUTICALS, INC. | ||||||
Date: May 18, 2020 | By: |
/s/ Peter Kies |
||||
Peter Kies | ||||||
Chief Financial Officer |
1 Year Inovio Pharmaceuticals Chart |
1 Month Inovio Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions